Between October 18–21, this website will move to a new web address (from health.gov to odphp.health.gov). During that time, some functions might not work as expected. We appreciate your patience and understanding as we’re working to make this transition as smooth as possible.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States

About this resource:

HHS Non-systematic Review

Source: National Institutes of Health

Last Reviewed: March 2022

Workgroups: HIV Workgroup

In this report, the Panel on Treatment of HIV in Pregnancy and Prevention of Perinatal Transmission (the Panel) provides recommendations on HIV screening in pregnancy, the treatment of pregnant people with HIV, and the use of antiretroviral (ARV) drugs to prevent perinatal (vertical) transmission of HIV from mother to infant. 

Since some ART drugs have not been sufficiently studied for evidence of harm to mothers and infants, the Panel uses a graded approach to recommendations — noting, for example, when there is insufficient data to recommend a medicine for pregnant people. 

In the latest version of the recommendations, the Panel updated and added to the guidelines to include new data and publications in several sections. 

Read more about this resource

Objectives related to this resource (1)

Reduce the rate of mother-to-child HIV transmission — HIV‑06
Improving

Suggested Citation

1.

U.S. Department of Health and Human Services, Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. (2022). Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Retrieved from https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines